The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2026 | Disease biology and treatment challenges in appendix cancer
John Paul Shen, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the unique features of appendix cancer, a relatively uncommon gastrointestinal tumor, highlighting its heterogeneity, with significant differences between high-grade and low-grade tumors. Low-grade tumors do not respond to traditional chemotherapy but have better survival rates, and appendix cancer tends to remain in the abdominal cavity, unlike colon cancer, which often metastasizes to the liver. This interview took place at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
